Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

483 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs.
Charles-Schoeman C, Burmester G, Nash P, Zerbini CA, Soma K, Kwok K, Hendrikx T, Bananis E, Fleischmann R. Charles-Schoeman C, et al. Among authors: fleischmann r. Ann Rheum Dis. 2016 Jul;75(7):1293-301. doi: 10.1136/annrheumdis-2014-207178. Epub 2015 Aug 14. Ann Rheum Dis. 2016. PMID: 26275429 Free PMC article. Clinical Trial.
Safety of extended treatment with anakinra in patients with rheumatoid arthritis.
Fleischmann RM, Tesser J, Schiff MH, Schechtman J, Burmester GR, Bennett R, Modafferi D, Zhou L, Bell D, Appleton B. Fleischmann RM, et al. Ann Rheum Dis. 2006 Aug;65(8):1006-12. doi: 10.1136/ard.2005.048371. Epub 2006 Jan 5. Ann Rheum Dis. 2006. PMID: 16396977 Free PMC article. Clinical Trial.
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.
Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Sieper J, Emery P, Keystone EC, Schiff MH, Mease P, van Riel PL, Fleischmann R, Weisman MH, Weinblatt ME. Furst DE, et al. Among authors: fleischmann r. Ann Rheum Dis. 2007 Nov;66 Suppl 3(Suppl 3):iii2-22. doi: 10.1136/ard.2007.081430. Ann Rheum Dis. 2007. PMID: 17934088 Free PMC article. Review. No abstract available.
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.
Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, Goel N, Brezinschek HP, Innes A, Strand V. Fleischmann R, et al. Ann Rheum Dis. 2009 Jun;68(6):805-11. doi: 10.1136/ard.2008.099291. Epub 2008 Nov 17. Ann Rheum Dis. 2009. PMID: 19015206 Free PMC article. Clinical Trial.
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.
Furst DE, Keystone EC, Kirkham B, Kavanaugh A, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Burmester GR, Braun J, Emery P, Winthrop K, Bresnihan B, De Benedetti F, Dörner T, Gibofsky A, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH. Furst DE, et al. Among authors: fleischmann r. Ann Rheum Dis. 2008 Dec;67 Suppl 3:iii2-25. doi: 10.1136/ard.2008.100834. Ann Rheum Dis. 2008. PMID: 19022808 No abstract available.
Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.
Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, Nash P, Amante EJ, Churchill M, Park W, Pons-Estel BA, Doyle MK, Visvanathan S, Xu W, Rahman MU. Emery P, et al. Arthritis Rheum. 2009 Aug;60(8):2272-83. doi: 10.1002/art.24638. Arthritis Rheum. 2009. PMID: 19644849 Free article. Clinical Trial.
483 results